Briciclib

Overview

Briciclib (ON 014185) is a eukaryotic translation initiation factor 4E ( eIF4E ) inhibitor. Briciclib exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer , gastric cancer , and esophageal cancer cells. Briciclib reduces the expression of cyclin D1 and c-Myc , and enhances the expression of P53 and Cleaved Caspase 3 pro- apoptotic proteins. Briciclib can be used for the study of hematological system tumors and solid tumors.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Eukaryotic Initiation Factor (eIF) | Products > Signaling Pathways > CDK | Products > Signaling Pathways > c-Myc | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-16366
• CAS No.: 865783-99-9
• Molecular Formula: C19H23O10PS
• Molecular Weight: 474.42
• Purity: 99.45%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Availability: In-stock

Source

Original product source